MedTrace Logo

Special Drug Use-results Surveillance of Tafinlar/Mekinist

NCT06262919 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2025-12-30

No results posted yet for this study

Summary

This is a prospective, multicenter, single-arm, non-interventional and observational J-PMS conducted by the central registration system and operated in Electronic data capture.

Conditions

  • BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

Interventions

DRUG

Tafinlar/Mekinist

There is no treatment allocation. Patients administered Tafinlar/Mekinist by prescription that have started before inclusion of the patient into the study will be enrolled.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
6 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-09
Primary Completion
2031-12-31
Completion
2031-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06262919 on ClinicalTrials.gov